About
Jennifer Doudna is a Nobel Prize-winning biochemist best known for co-developing CRISPR-Cas9 genome editing with Emmanuelle Charpentier. She is a professor of chemistry and molecular and cell biology at UC Berkeley and founder/president of the Innovative Genomics Institute. Doudna has also co-founded multiple CRISPR-related companies, including Caribou Biosciences, Intellia Therapeutics, Mammoth Biosciences, Scribe Therapeutics, and Azalea Therapeutics.
Areas of interest
biotechgenome editingCRISPRcell and gene therapymolecular biologyRNA biologydiagnosticshuman healthagricultureclimatescientific ethics